Empirical antibiotic therapy of sepsis in surgical intensive care unit

Area of Science:

• Infectious Diseases
• Critical Care Medicine
• Microbiology

Background:

• Sepsis management in intensive care units (ICUs) requires effective empirical antibiotic therapy.
• Identifying common causative agents and their antimicrobial susceptibility is crucial for optimizing treatment guidelines.
• Previous data on local antimicrobial resistance patterns in surgical ICUs is essential for evidence-based practice.

Purpose of the Study:

• To develop empirical antibiotic therapy guidelines for sepsis in an ICU setting.
• To determine the antimicrobial susceptibility patterns of prevalent bacterial pathogens causing sepsis.
• To guide clinicians in selecting appropriate antibiotics when the causative agent is unknown.

Main Methods:

• Retrospective analysis of clinical and microbiological data from 32 severe sepsis patients in a surgical ICU.
• Antimicrobial susceptibility testing using the disk diffusion method (CLSI standards).
• APACHE II score used for illness severity assessment; Mann-Whitney and chi2 tests for statistical analysis.

Main Results:

• Acinetobacter baumannii showed excellent susceptibility to ampicillin/sulbactam and carbapenems.
• Pseudomonas aeruginosa demonstrated good susceptibility to ceftazidime and carbapenems.
• Methicillin-resistant Staphylococcus aureus (MRSA) exhibited good susceptibility to vancomycin and linezolid.

Conclusions:

• Empirical antibiotic therapy in ICUs should target common pathogens like Acinetobacter baumannii, Pseudomonas aeruginosa, and MRSA.
• Specific antibiotic recommendations based on susceptibility data include ampicillin/sulbactam and carbapenems for A. baumannii, ceftazidime and carbapenems for P. aeruginosa, and vancomycin/linezolid for MRSA.
• These findings support the development of updated, localized guidelines for empirical antibiotic treatment of sepsis in ICUs.